Business Context and Reporting Period
This Form 8-K is a current report filed by Cyclacel Pharmaceuticals, Inc. (not Bio Green Med Solution, Inc.) on December 28, 2006, covering events occurring on December 21, 2006. The registrant is a Delaware corporation focused on pharmaceutical development, with principal executive offices in Berkeley Heights, NJ.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation arrangements.
| Officer | 2007 Base Salary | 2006 Cash Bonus | 2006 Options Granted |
|---|---|---|---|
| Spiro Rombotis (CEO & President) | $425,000 | $175,000 | 160,000 |
| Paul McBarron (COO & EVP Finance) | $280,000 | $110,000 | 100,000 |
| Dr. Judy H. Chiao (VP Clinical Dev) | $275,000 | $100,000 | 80,000 |
| Dr. John Francis Womelsdorf (VP Business Dev) | $254,000 | $25,000 | 50,000 |
| Dr. Robert Jackson (SVP & CSO) | $250,000 | $0 | $0 |
Material Changes
The primary material change reported is the approval of 2007 annual base salaries and 2006 cash bonuses for named executive officers. Additionally, stock options were granted to four executives on December 21, 2006, at an exercise price of $6.95 per share.
Outlook, Risks, and Unusual Items
Compensation Structure: The 2006 cash bonuses were contingent upon the completion of specific corporate objectives, including:
- Initiation of a Phase IIb trial for selicilib in 3rd-line NSCLS (Q2 2006).
- Initiation of a Phase I hematology study for sapacitabine (Q2 2006).
- Submission of an IND for the CYC116 Aurora kinase inhibitor (Q4 2006).
- Interim data reports for the sapacitabine Phase I study (Q4 2006).
Option Vesting: Granted options vest 25% on December 21, 2007, with the remainder vesting monthly over the subsequent 36 months, fully vesting by December 21, 2010. Options expire on December 20, 2016.
Risks: The filing does not explicitly list new risks or contingencies beyond the standard operational milestones tied to executive compensation.
Investor Verification Checklist
- Verify the actual achievement of the four specific clinical milestones (selicilib, sapacitabine, CYC116) that triggered the 2006 bonuses.
- Confirm the total number of shares outstanding post-grant to assess dilution from the 390,000 new options.
- Review the company's cash position to ensure it can fund the $410,000 in total cash bonuses awarded.
- Check subsequent filings for updates on the Phase IIb and Phase I trials mentioned in the bonus criteria.